Skip to Content
Merck
CN

Key Documents

View All Documentation

822854

TSKgel® SuperSW mAb HR (4 µm) HPLC Column

L x I.D. 30 m × 7.8 mm, diol phase

Synonym(s):

TSKgel® Size Exclusion (SW-Type) HPLC Column

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
41115711
NACRES:
NB.21
L × i.d.:
30 m × 7.8 mm
Particle size:
4 μm
Matrix active group:
diol phase
Pore size:
250 Å pore size
Matrix:
silica particle platform
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

TSKgel® SuperSW mAb HR HPLC Column, phase diol, L × I.D. 30 m × 7.8 mm, 4 μm particle size

material

stainless steel

agency

suitable for USP L20, suitable for USP L59

product line

TSKgel®

manufacturer/tradename

Tosoh SuperSW mAb HR, 22854

parameter

≤0.5 M salt concentration, 0-100% aqueous soluble organic solvents, 1 mL/min flow rate, 10-30 °C temperature, 120 bar max. pressure

technique(s)

HPLC: suitable

L × I.D.

30 m × 7.8 mm

matrix

silica particle platform

matrix active group

diol phase

particle size

4 μm

pore size

250 Å pore size

operating pH

2.5-7.5

separation technique

size exclusion (SEC)

General description

The TSKgel SuperSW and UltraSW mAb columns consist of three specialized columns designed for the separation and analysis of monoclonal antibodies (mAb). While mAbs can be analyzed using many different modes of HPLC, size exclusion is best to determine the level of aggregation, dimer formation, and fragmentation, making it the best method for heterogeneity studies. TSKgel SuperSW mAb HR columns are optimized for high resolution analysis of mAb monomer and dimer; these 30 cm x 7.8 mm ID slica-based stainless steel columns offer reduced lot-to-lot variation, long column life, reduction of unspecified adsorption, and superior recovery of aggregates. The TSKgel SuperSW mAb columns utilize a unique pore-controlled technology, which produces a shallow calibration curve in the molecular weight region of a typical monoclonal antibody. The calibration curve for the TSKgel SuperSW mAb HR column is similar to that of the industry-leading TSKgel G3000SWxl column and has a shallower slope than the TSKgel UltraSW Aggregate column around the molecular weight range of gamma-globulin. This shallow calibration curve produces high resolution separations.

Application

TSKgel® superSW mAb HR HPLC column may be used in the separation of monoclonal antibodies using size exclusion chromatography (SEC).

Physical form

Shipped in 0.05% NaN3 and 0.1 M Na2SO4 in 0.1 M phosphate buffer, pH 6.7.

Other Notes

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

TSKgel is a registered trademark of Tosoh Corporation

Still not finding the right product?

Explore all of our products under TSKgel® SuperSW mAb HR HPLC Column

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Columns and Analytical Standards for Protein SEC

Size-exclusion chromatography (SEC) columns and ready-to-use standards facilitate method development and increase robustness of protein SEC methods.

蛋白质SEC的色谱柱和分析标准品

体积排阻色谱（SEC）色谱柱和现成的标准品有助于方法开发，并提高蛋白质SEC方法的耐用性。

Alexander Rau et al.
mAbs, 13(1), 1902034-1902034 (2021-03-24)
Dual targeting of surface receptors with bispecific antibodies is attracting increasing interest in cancer therapy. Here, we present a novel bivalent and bispecific antagonistic molecule (Dab-Fc) targeting human epidermal growth factors 2 and 3 (HER2 and HER3) derived from the
null
Alexander Rau et al.
Molecular cancer therapeutics, 19(7), 1474-1485 (2020-05-21)
The frequent activation of HER3 signaling as a resistance mechanism to EGFR-targeted therapy has motivated the development of combination therapies that block more than one receptor tyrosine kinase. Here, we have developed a novel tetravalent, bispecific single-chain diabody-Fc fusion protein

Global Trade Item Number

SKUGTIN
82285404061833672082